Loading...
Market
Story
Genentech Acquires Regor's CDK Inhibitors in Definitive Purchase Agreement for $850 Million
Sep 30, 2024, 08:46 AM
Genentech has announced the acquisition of Regor's portfolio of next-generation CDK inhibitors for $850 million upfront, with potential for additional milestone payments. The definitive purchase agreement aims to enhance Genentech's capabilities in the treatment of breast cancer.
View original story
Similar markets
Breakthrough Therapy • 25%
Fast Track • 25%
Orphan Drug • 25%
None • 25%
Yes • 50%
No • 50%
Complete Response (CR) • 25%
Partial Response (PR) • 25%
Stable Disease (SD) • 25%
Progressive Disease (PD) • 25%
Yes • 50%
No • 50%
Cancer Treatment • 25%
Neurology Treatment • 25%
Immunology Treatment • 25%
Other Treatment • 25%
Lung Cancer • 25%
Breast Cancer • 25%
Colorectal Cancer • 25%
Other • 25%
Afami-cel • 25%
Cosibelimab • 25%
Adagrasib-Cetuximab • 25%
Other • 25%
Merck & Co. • 25%
AstraZeneca • 25%
Roche • 25%
Other • 25%
Johnson & Johnson • 25%
Pfizer • 25%
AstraZeneca • 25%
Roche • 25%
None • 25%
One • 25%
Two • 25%
Three or more • 25%
